ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 135

Evaluation Of The Quality Of Life and Sleep In Patients With Benign Joint Hypermobility Syndrome

Ilknur Albayrak1, Halim Yilmaz1, Ekrem Akkurt2, Ali Salli3 and Gulten Karaca4, 1The Department of Physical Medicine and Rehabilitation, Konya Education and Research Hospital, MD, Konya, Turkey, 2The Department of Physical Medicine and Rehabilitation, Konya Education and Research Hospital, Konya, Turkey, MD, Konya, Turkey, 3The Department of Physical Medicine and Rehabilitation, Necmettin Erbakan University, Meram Faculty of Medicine, MD, KONYA, Turkey, 41The Department of Physical Medicine and Rehabilitation, Konya Education and Research Hospital, Konya, Turkey, MD, Konya, Turkey

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fatigue, hypermobility, pain and sleep

  • Tweet
  • Email
  • Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders and Pain I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Traction injuries at tendon or ligament attachment sites, joint instability, low back, back and neck pain can be seen in patients with benign joint hypermobility syndrome (BJHS). The most important complaint of such patients is pain. Due to pain, impairment in the quality of sleep and life and fatigue resulting in effects on psychological condition. In this study, we aimed to evaluate pain, fatigue, quality of sleep, depression level and quality of life in patients with BJHS and compare these parameters with those of healthy controls.

Methods: 26 patients who had diagnosed with BJHS according to Brighton diagnostic criteria and 40 healthy controls were included in the study. In all patients and healthy controls, pain severity evaluation was performed using visual analog scale (VAS), fatigue severity was performed using Checklist Individual Strength Scale (CIS), quality of sleep was performed using Pittsburg Sleep Quality Index (PSQI), depression level was evaluated using Beck Depression Scale (BDS), and quality of life was evaluated using Short Form-36 (SF-36).

Results: Mean age was 31.4±7.6 years in the patient group, and 31.3±6.9 years in the control group. There were no statistically significant differences between the two groups with respect to age, gender, body mass index and marital status (p>0.05). In the patient group, VAS score during movement was 6.6±0.9. Total CIS scores were 4.3±1.09 in the patient group and 3.2±1.2 in the control group (p=0.001), global PSQI scores were 7.8±3.1 in the patient group and 4.9±2.9 in the control group (p<0.001), BDS scores were 17.6±8.8 in the patient group and 6.8±5.8 in the control group (p<0.001), SF-36 physical component scale scores were 52.7±14.6 in the patient group and 56.09±9.07 in the control group (p>0.05), and SF-36 mental component scale scores were 42.01±15.04 in the patient group and 54.3±10 in the control group (p<0.001).

Conclusion:

This study shows that the levels of pain, fatigue and depression are increased and the quality of sleep and quality of life are adversely affected in patients with BJHS. Therefore, patients with BJHS should be evaluated in terms of pain, fatigue, depression, quality of sleep and quality of life during their diagnostic procedures and follow-up, and multi-faceted treatment programs should be planned.


Disclosure:

I. Albayrak,
None;

H. Yilmaz,
None;

E. Akkurt,
None;

A. Salli,
None;

G. Karaca,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-the-quality-of-life-and-sleep-in-patients-with-benign-joint-hypermobility-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology